前列腺癌弥漫性腹膜转移经[89Zr]Zr-PSMA-617 PET/CT揭示
本文报告一例64岁前列腺癌根治术后患者,前列腺特异性抗原持续升高,但既往多次[68Ga]Ga-PSMA-11 PET/CT及[18F]FDG PET/CT均为阴性。[89Zr]Zr-PSMA-617 PET/CT清晰显示弥漫性腹膜转移及局部复发,提示该新型PSMA示踪剂PET显像的潜在价值。
要点
- 64岁前列腺癌根治术后患者前列腺特异性抗原持续升高,既往[68Ga]Ga-PSMA-11 PET/CT及[18F]FDG PET/CT均阴性。
- [89Zr]Zr-PSMA-617 PET/CT清晰显示弥漫性腹膜转移及局部复发,为既往常规PET/CT未发现的病灶。
- 本病例提示[89Zr]Zr-PSMA-617 PET显像具有潜在应用价值。
核心结论
- 本病例表明[89Zr]Zr-PSMA-617 PET显像具有潜在应用价值,可显示既往常规PET/CT未发现的前列腺癌弥漫性腹膜转移及局部复发。
研究设计与样本
- 个案报告:一例64岁前列腺癌根治术后患者,因前列腺特异性抗原持续升高行[89Zr]Zr-PSMA-617 PET/CT检查。
主要发现
- 患者既往多次[68Ga]Ga-PSMA-11 PET/CT及[18F]FDG PET/CT均为阴性。
- [89Zr]Zr-PSMA-617 PET/CT清晰显示弥漫性腹膜转移及前列腺癌局部复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report an interesting case of a 64-year-old man with a history of radical prostatectomy for prostate cancer. The patient presented with steady increasing prostate-specific antigen levels, but with negative findings on previous multiple conventional prostate-specific membrane antigen (PSMA) PET/CT (with [68Ga]Ga-PSMA-11) and [18F]FDG PET/CT. A recently introduced PSMA tracer using long-lived 89Zr (half-life 3.3 days), [89Zr]Zr-PSMA-617, was administered in attempt to localize potential local recurrence or metastasis. [89Zr]Zr-PSMA-617 PET/CT clearly revealed diffuse peritoneal carcinomatosis and local recurrence of the prostate cancer, which were unidentified on previous conventional PET/CT scans. This case highly demonstrates the potential of PET imaging with the novel PSMA tracer [89Zr]Zr-PSMA-617.
引用
- Bastian MB, Burgard C, Blickle A, et al. Diffuse Peritoneal Carcinomatosis of Prostate Cancer Unveiled by [89Zr]Zr-PSMA-617 PET/CT. Clin Nucl Med. 2024. PMID: 39774158. doi:10.1097/RLU.0000000000005604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。